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Triclosan-induced genes Rv1686c-
Rv1687c and Rv3161c are not 
involved in triclosan resistance in 
Mycobacterium tuberculosis
Andromeda Gomez1,2,†, Núria Andreu1,‡, Mario Ferrer-Navarro1,§, Daniel Yero1 & 
Isidre Gibert1,2
A key issue towards developing new chemotherapeutic approaches to fight Mycobacterium tuberculosis 
is to understand the mechanisms underlying drug resistance. Previous studies have shown that 
genes Rv1686c-Rv1687c and Rv3161c, predicted to encode an ATP-binding cassette transporter and a 
dioxygenase respectively, are induced in the presence of triclosan and other antimicrobial compounds. 
Therefore a possible role in drug resistance has been suggested for the products of these genes although 
no functional studies have been done. The aim of the present study was to clarify the role of Rv1686c-
Rv1687c and Rv3161c in M. tuberculosis resistance to triclosan and other drugs. To this end, deficient 
mutants and overproducing strains for both systems were constructed and their minimal inhibitory 
concentration (MIC) against over 20 compounds, including triclosan, was evaluated. Unexpectedly, 
no differences between the MIC of these strains and the wild-type H37Rv were observed for any of the 
compounds tested. Moreover the MIC of triclosan was not affected by efflux pump inhibitors that inhibit 
the activity of transporters similar to the one encoded by Rv1686c-Rv1687c. These results suggest that 
none of the two systems is directly involved in M. tuberculosis resistance to triclosan or to any of the 
antimicrobials tested.
Tuberculosis remains one of the most important infectious diseases worldwide, killing more than 1.5 million 
people each year1. New drugs are urgently needed to shorten the duration of the current treatment, and to treat 
Mycobacterium tuberculosis strains resistant to existing antibiotics. The unusual mycobacterial cell wall consti-
tutes a proved target for the development of new antimycobacterial drugs (for a review, see reference 2). In fact, 
the current front line treatment regimen relies on isoniazid (INH), a drug that compromises the integrity of the 
cell wall by inhibiting the biosynthesis of mycolic acids. Specifically, INH inhibits the enoyl acyl carrier protein 
reductase InhA, upon activation by the mycobacterial catalase-peroxidase enzyme KatG3–6. Most clinical isolates 
resistant to INH carry mutations in katG7, therefore compounds that inhibit InhA but that do not require activa-
tion by KatG, have great promise as novel drugs for combating drug resistant strains.
One such compound is triclosan, a biocide with a high antibacterial activity used as an ingredient of diverse 
products like soaps, detergents, toothpastes, dishwashing liquids and lotions, among others8. Triclosan inhib-
its InhA from M. tuberculosis without the need for prior activation9–11. However, triclosan is less potent than 
INH and thus must be used at higher concentrations, causing broader disruption of bacterial cell wall functions 
and upregulation of many genes encoding transport proteins and membrane-bound proteins in M. tuberculosis 
and in many other bacteria12–15. Nevertheless, triclosan has been used as a starting point for structure-based 
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development of a series of alkyl diphenyl ethers that are stronger inhibitors of InhA and can prevent growth of 
both sensitive and INH-resistant strains16–19.
Betts and collaborators studied the transcriptional response of M. tuberculosis to triclosan in order to better 
understand its mechanism of action12. This study exposed two possible detoxification systems that were highly 
induced after treatment with triclosan: an ABC transporter encoded by Rv1686c-Rv1687c, similar to known anti-
biotic resistance systems, and a dioxygenase encoded by Rv3161c with similarity to several bacterial aromatic 
dioxygenases. It was suggested that the product of these genes could be involved in M. tuberculosis resistance to 
triclosan. The fact that the more active triclosan derivatives failed to induce these genes was proposed to contrib-
ute to their improved whole-cell activity compared to triclosan16,17.
Both sets of genes are also induced in response to treatment with compounds such as carbonyl cyanide 
m-chlorophenylhydrazone (CCCP), the antitubercular ARP4, or 2,4-dinitrophenol13. Genes Rv1686c-Rv1687c 
are also induced by lupulone, a compound extracted from hops (Hurnulus lupulus) that exhibits a good activity 
against M. tuberculosis20. Rv3161c is also induced by thioridazine21 and compounds SRI#967 and SRI#919022, all 
of which contain benzene ring structures like triclosan. It has therefore been proposed that the putative dioxy-
genase Rv3161c could hidroxylate benzenes, thus being partly responsible for M. tuberculosis natural resistance 
to them22.
Despite all the data suggesting the involvement of these genes in M. tuberculosis drug resistance, to our knowl-
edge, no functional studies have been reported. A better understanding of M. tuberculosis detoxification mech-
anisms is important in the development of new drugs since they are relevant both in natural resistance and in 
acquired resistance. For example, overexpression of detoxification mechanisms such as efflux pumps and degra-
dation or modification enzymes could lead to a low-level resistance favouring the acquisition of chromosomal 
mutations conferring higher levels of drug resistance23–25. Therefore the aim of the present study was to clarify the 
role of Rv1686c-Rv1687c and Rv3161c in M. tuberculosis resistance to triclosan and other drugs. Using mutant 
and overexpressing strains for each system we have found that these genes are not necessary for resistance to 
triclosan or to any of the other compounds here tested.
Results and Discussion
A previous transcriptional study of M. tuberculosis response to triclosan showed that genes Rv1686c-Rv1687c 
and Rv3161c are highly induced, and a possible role of the products of these genes in triclosan detoxification was 
suggested12,16. In order to clarify the potential involvement of these genes in drug resistance, firstly, we studied 
expression of Rv1687c and Rv3161c by qRT-PCR after exposing the wild-type M. tuberculosis H37Rv strain to 
triclosan (5× MIC) or to DMSO (untreated control) for 2 hours so as to reproduce the approach previously 
described by others12. Our results showed that triclosan leads to a 1002.67 (1001.84–1003.49) and a 1366.83 
(1366.36–1367.30) fold increase in the expression of Rv1687c and Rv3161c, respectively, confirming that triclosan 
strongly induces these systems. In fact, the induction that we observed was 5 times higher than that previously 
described. This is probably due to the higher concentration of triclosan that we used since the MIC for triclosan 
that we obtained was also higher (21.7 μ g/mL vs 8 μ g/mL12 or 12.5 μ g/mL16).
Once the induction of these genes was confirmed, we constructed M. tuberculosis H37Rv knockout 
mutant strains for each system using phage-mediated allelic exchange. To construct the knockout strain of 
Rv1686c-Rv1687c, named Δ 8687, 608 bp out of 681 bp of Rv1686c and 730 bp out of 768 bp of Rv1687c were 
deleted and a hygromycin cassette inserted (Fig. 1). Likewise, to construct Δ Rv3161c, 991 bp out of 1149 bp were 
deleted and a hygromycin cassette inserted (Fig. 2). Allelic exchange was confirmed by PCR using primers specific 
Figure 1. Construction and confirmation of Δ8687. (a) Physical map of the region containing genes 
Rv1686c-Rv1687c depicting primers used to construct and confirm the knock-out strain. (b) Confirmation 
PCRs. Lane 1: H37Rv and lane 2: Δ 8687, amplified with primers 8687Up and 8687Lw (1.5 and 2 kb, 
respectively); lane 3: H37Rv and lane 4: Δ 8687, amplified with HygOut1 and 8687Up (no amplification and 
285 pb, respectively); lane 5: H37Rv and lane 6: Δ 8687, amplified with HygOut2 and 8687Lw (no amplification 
and 358 pb, respectively). MWM: molecular weight marker.
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to the hygromycin cassette and to the genomic flanking regions. PCR products would only be obtained if the 
hygromycin cassette had inserted into the correct location on the chromosome. PCR products of the expected 
size were obtained for the knockout strains; no products were obtained for the wild-type strain (Figs 1 and 2). 
PCR over the region of disruption further confirmed mutant construction by showing an increase in size corre-
sponding to insertion of the hygromycin cassette at this location. These PCRs also allowed discriminating single 
from double recombinants.
We also constructed M. tuberculosis overexpressing strains for each system, using the replicative expression 
vector pMV261 with the strong promoter from gene hsp60, resulting in strains H37Rv (pMV261 + 8687) and 
H37Rv (pMV261 + 3161). Overexpression of Rv1687c and Rv3161c was confirmed measuring gene expres-
sion by qRT-PCR (6.71 and 9.39, and 127.96 and 160.67 fold increase, respectively, for two independent clones 
of each strain), and the overproduced proteins were confirmed by 2D-PAGE and MALDI-TOF MS/MS (see 
Supplementary Figs S1 and S2). Neither the mutant nor the overexpressing strains presented any evident pheno-
types in terms of colony morphology, in vitro growth or growth inside macrophages (Fig. 3).
We then determined the MICs of over 20 compounds including antibiotics, dyes and biocides against the wild-type 
parental strain M. tuberculosis H37Rv, the control strain pMV261 (containing vector pMV261), three independent 
clones of each knockout mutant strain, and two independent clones of each overexpressing strain. Unexpectedly, no 
significant differences in the MICs for any of the tested compounds, including triclosan, were observed (Table 1). 
These results are inconsistent with a possible role for these genes in resistance to triclosan or to the other drugs tested.
To further confirm these results we assessed the effect of efflux pump inhibitors (reserpine, CCCP, verapamil 
and o-vanadate) on the MIC of triclosan in the wild-type H37Rv strain. These compounds inhibit the activity 
of transporters including ABC transporters that are similar to the one encoded by Rv1686c-Rv1687c. First, we 
determined the MIC of the inhibitors in H37Rv (reserpine: 48 μ g/mL, CCCP: 5 μ g/mL, verapamil: 80 μ g/mL and 
o-vanadate: >96 μ g/mL). Then, we evaluated the effect of the efflux pump inhibitors on the MIC of triclosan, 
using the inhibitors at subinhibitory concentrations to ensure that the cellular viability was not affected (reser-
pine: 12 μ g/mL, CCCP: 1.25 μ g/mL, verapamil: 20 μ g/mL and o-vanadate: 9 μ g/mL). No changes were observed 
in the MIC of triclosan with any of the inhibitors tested. Therefore, with our experimental procedure, we did not 
find any evidence supporting the implication of efflux pumps such as Rv1686c-Rv1687c in mediating triclosan 
resistance in M. tuberculosis.
Altogether the results presented here strongly suggest that the products of genes Rv1686c-Rv1687c and Rv3161c 
are not involved in resistance to triclosan or to any of the other compounds tested in M. tuberculosis. It could be spec-
ulated that induction of these genes in response to triclosan is part of an unsuccessful attempt of the bacteria to coun-
teract the nonspecific toxic effects caused by triclosan when used at high concentrations, such as the ones needed 
to kill M. tuberculosis because of its moderate inhibitory activity against its target InhA. This would also explain the 
non-induction of Rv1686c-Rv1687c and Rv3161c by the more active triclosan-derivatives as they have an increased 
potency towards InhA resulting in a more narrowed mode of action and a lower MIC17. Although transcriptional 
studies are important and shed light onto many aspects of the mechanism of action and bacterial response to drugs, 
the results obtained here highlight the importance of corroborating transcriptional data with functional studies.
Methods
Bacterial strains, plasmids, media and growth conditions. Strains and plasmids used are listed in 
Supplementary Table S1. M. tuberculosis and M. smegmatis were grown in Middlebrook 7H9 supplemented with 
0.05% Tween 80 and 10% albumin-dextrose-catalase (ADC), or on 7H10 agar supplemented with 10% oleic 
Figure 2. Construction and confirmation of Δ3161. (a) Physical map of the region containing gene Rv3161c 
depicting primers used to construct and confirm the knock-out strain. (b) Confirmation PCRs. Lane 1: 
H37Rv and lane 2: Δ 3161, amplified with primers 3161UpBam and 3161LwHin (1.1 and 2 kb, respectively); 
lane 3: H37Rv and lane 4: Δ 3161, amplified with HygOut1 and 3161UpBam (no amplification and 310 bp, 
respectively); lane 5: H37Rv and lane 6: Δ 3161, amplified with HygOut2 and 3161LwHin (no amplification and 
354 bp, respectively). MWM: molecular weight marker.
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acid-albumin-dextrose-catalase (OADC). Escherichia coli was grown in Luria-Bertani (LB) medium. The fol-
lowing antibiotics were used when required: hygromycin B (100 μ g/mL for mycobacteria and E. coli), kanamycin 
(25 μ g/mL for mycobacteria, 50 μ g/mL for E. coli), and ampicillin (50 μ g/mL for E. coli). All cultures were incu-
bated at 37 °C.
Quantitative Real-time PCR. Total RNA was extracted from 30 mL of M. tuberculosis mid-log cultures 
in triplicate using the GTC/Trizol method26,27. The RNA was cleaned with 75% ethanol and purified using an 
RNeasy Minikit (Qiagen). RNAs were treated with Turbo DNAse (Ambion, Life Technologies) and DNA con-
tamination was checked by PCR. Quality and quantity of RNA were determined using a Bio-analyser (Agilent).
cDNA was synthesized using the high capacity cDNA reverse transcription kit (Applied Biosystems). Primers 
and TaqMan probes were designed by Applied Biosystems for Rv1687c, Rv3161c and sigA genes (Supplementary 
Table S2). qRT-PCR was performed on an Applied Biosystems 7500 Real-Time System using TaqMan univer-
sal PCR master mix (Applied Biosystems). Linear amplification and amplification efficiencies for each TaqMan 
primer/probe were determined. Real-time analysis was performed in quadruplicate on RNA from three inde-
pendent cultures. Quantification of sigA expression served as an internal control. Fold change was calculated as a 
ratio of the arbitrary expression units, standardised to sigA28.
Construction of mutant strains. Phage-mediated allelic exchange was used to create the M. tuberculosis 
Δ Rv1686c-Rv1687c (Δ 8687) and Δ Rv3161c mutant strains as previously described29. Upstream and downstream 
flanking sequences from genes Rv1686c-Rv1687c and Rv3161c (Figs 1 and 2) were amplified using primers listed 
in Supplementary Table S2. The flanking regions were cloned in pGEM-T® (Promega), verified by sequencing and 
cloned into pYUB854 flanking the hygromycin cassette. The obtained plasmids pYUB854Δ 8687 and pYUB854Δ 
Rv3161c were digested with PacI, cloned in the temperature-sensitive shuttle phasmid phAE159, packaged 
using MaxPlax Kit (Epicenter) and transduced in E. coli HB101 according to the manufacturer’s instructions. 
Recombinant phasmids were verified by PacI digestion and PCR, and were electroporated in M. smegmatis mc2 
155 as previously described30. A high titer lysate prepared at the permissive temperature (30 °C) was used to 
transduce M. tuberculosis at the non-permissive temperature (37 °C). Transductants were selected on hygromycin 
and successful deletion was confirmed by PCR using primers that anneal to the flanking regions and hygromycin 
cassette specific primers (Figs 1 and 2, and Supplementary Table S2).
Construction of overexpressing strains. Genes Rv1686c-Rv1687c and Rv3161c were amplified by PCR 
using primers described in Supplementary Table S2, and cloned into pMV261 using BalI-EcoRI and BamHI–
HindIII, respectively. The resulting plasmids pMV261 + 8687 and pMV261 + 3161 were verified by sequencing 
Figure 3. Growth of the parental, mutant and overexpressing strains in (a) Middlebrook 7H9 supplemented 
with 0.05% Tween 80 and 10% ADC, and (b,c) inside J774 macrophages. Results are expressed as the average 
and standard deviation of duplicates of at least two independent experiments.
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and electroporated into M. tuberculosis H37Rv as previously described30. The recombinant strains were checked 
by recovering the plasmid after transformation into E. coli.
Two-Dimensional Electrophoresis and Protein identification. Protein extracts were obtained from 
140 mL of M. tuberculosis mid-log cultures grown in 7H9–0.05% Tween 80 supplemented with 10% ADC. Cells 
were pelleted by centrifugation and washed twice with sterile PBS 1X. Pellets were resuspended in lysis solution 
(7M Urea, 2 M Thiourea, 4% CHAPS, 4% ASB-14) and then sonicated (20 cycles: 30 sec ON/1 min OFF) at 4 °C 
in ice water, and finally centrifuged to remove cells debris. Samples were then quantified and purified using 2-D 
Quant Kit and 2-D Clean-Up Kit (GE Healthcare) respectively. For two-dimensional gel electrophoresis (2DE) 
IPGphor II and EttanSix (GE Healthcare) were used for the first and second dimension respectively. 100 μ g of 
each sample was separated by 2DE in 24 cm length, 6–9 pH strips in the first dimension and in a 12% SDS-PAGE 
for the second dimension according to manufacturer instructions. 2DE gels were silver stained as described else-
where31. Image analysis was performed using Progenesis SameSpot software (Nonlinear Dynamics). After image 
analysis, differential spot was excised and identified as previously described by mass spectrometry32.
Growth analysis of strains. M. tuberculosis wild type, mutant and overexpressing strains were grown to 
mid-log phase (OD600 0.8–1) in 7H9 media as previously stated. The cells were then used to inoculate fresh 
medium to a starting OD600 of 0.01. Growth was analysed by taking daily OD600 readings.
In vitro infection of J774 murine macrophages. J 774 cells were maintained in Dulbecco’s min-
imal essential medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum. The cells were 
plated at a concentration of 5 ×  104 cells per well in 96-well tissue culture plates with clear bottoms (Corning® ) 
and allowed to adhere overnight. For the infection, mid-log phase M. tuberculosis were washed twice with 
PBS +  0.05% Tween, once with Dulbecco’s PBS and then allowed to stand for 5 min, before the supernatant were col-
lected. The bacteria were then diluted in DMEM and added to the J 774 cells at a concentration of ∼ 5 ×  105 cfu/well. 
After 4 h of infection at 37 °C in 5% CO2, macrophages were treated with 200 mg/L amikacin for 1 h and washed 
twice with PBS to eliminate any extracellular bacteria. Lastly, 200 μ L of complete DMEM was added to each well. 
Intracellular survival and growth was assessed by lysis of the monolayers by the addition of water followed by a 
30 min incubation at room temperature and enumeration of bacteria by serial dilution in PBS-Tween plating onto 




H37Rv pMV261 pMV261 + 8687 Δ8687 pMV261 + 3161 Δ3161
Triclosan 21.7 (21.7) 21.7 (21.7) 21.7 (21.7) 21.7 (21.7) 21.7 (21.7) 21.7 (21.7)
INH 0.062 (0.062–0.12) 0.12 (0.062–0.12) 0.12 (0.062–0.12) 0.062 (0.062–0.12) 0.062 (0.062) 0.093 (0.062–0.12)
Ethambutol 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1)
Streptomycin 0.125 (0.125) 0.125 (0.125) 0.125 (0.125) 0.125 (0.125) 0.125 (0.125) 0.125 (0.125)
Rifampicin 0.064 (0.016–0.064) 0.064 (0.032–0.064) 0.064 (0.032–0.064) 0.064 (0.016–0.064) 0.064 (0.064) 0.064 (0.032–0.064)
Clofazimine 0.12 (0.12–0.24) 0.12 (0.12–0.24) 0.12 (0.12) 0.12 (0.12) 0.12 (0.12–0.24) 0.12 (0.12–0.24)
Ethionamide 0.48 (0.24–0.48) 0.48 (0.24–0.48) 0.48 (0.48) 0.48 (0.48) 0.48 (0.24–0.48) 0.48 (0.24–0.48)
p–aminosalicylic acid 0.1 (0.1–0.2) 0.1 (0.1–0.2) 0.1 (0.1–0.2) 0.1 (0.1) 0.1 (0.1–0.2) 0.1 (0.1–0.2)
D–cycloserine 8 (8) 8 (8) 8 (8) 8 (8) 8 (8) 8 (8)
Kanamycin 2 (2) n.d. n.d. 2 (2) n.d. 2 (2)
Tetracycline 4 (2–8) 4 (4–8) 4 (4–8) 4 (4) 4 (4–8) 4 (4)
Erythromycin 100 (50–100) 100 (50–100) 100 (50–100) 100 (50–100) 100 (100) 100 (50–100)
Chloramphenicol 2.5 (2.5) 2.5 (2.5) 2.5 (2.5) 2.5 (2.5) 2.5 (2.5) 2.5 (2.5)
Gentamycin 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3)
Ofloxacin 0.25 (0.25) 0.25 (0.25) 0.25 (0.25) 0.25 (0.25) 0.25 (0.25) 0.25 (0.25)
Levofloxacin 0.125 (0.125) 0.125 (0.125) 0.125 (0.125) 0.125 (0.125) 0.125 (0.125) 0.125 (0.125)
Acriflavin 2 (2) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2)
Thioridazine hydrochloride 10 (5–10) 10 (5–10) 10 (10) 10 (10) 10 (10) 10 (10)
Amikacin 0.5 (0.5–1) 1 (1) 0.5 (0.5) 0.5 (0.5) 0.75 (0.5–1) 0.5 (0.5)
Ethidium bromide 2 (2) 1 (1–2) 2 (2) 1.5 (1–2) 2 (2) 1.5 (1–2)
Safranin 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1)
CTAB 25 (25) 25 (25) 25 (25) 25 (25) 25 (25) 25 (25)
Table 1.  MICs (μg/mL) of several antimicrobial compounds against M. tuberculosis H37Rv, pMV261, and 
the Rv1686c-Rv1687c and Rv3161c mutant and overexpressing strains. Results are expressed as the median 
and range (minimum-maximum) of duplicates of at least two independent experiments. Two independent 
clones of the overexpressing strains and three of the mutant strains were tested with similar results. n. d., non 
determined since pMV261 contains a kanamycin resistance selection marker.
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Antimicrobials agents and inhibitors. Triclosan, INH, ethambutol, rifampicin, clofazimine, ethion-
amide, p-aminosalicylic acid, D-cycloserine, tetracycline, erythromycin, gentamicin, ofloxacin, levofloxacin, 
acriflavine, thioridazine hydrochloride, reserpine, o-vanadate, CCCP, verapamil, and cetyltrimethyl ammonium 
chloride (CTAB) were obtained from SIGMA. Streptomycin, amikacin, and kanamycin were obtained from 
Apollo Chemicals Ltd. Chloramphenicol was obtained from Boehringer Mannheim, hygromycin B from Roche, 
safranin from Panreac, and ethidium bromide from Amresco. Stocks were prepared according to the manufactur-
er’s instructions, and aliquots kept at −20 °C were thawed just before use. For the MIC assays, drugs were diluted 
to the working concentration in Middlebrook 7H9 supplemented with 0.2% glycerol and 10% ADC.
MIC determination. MICs were determined by the resazurin microtitre assay (REMA) as previously 
described33. Briefly, mid-log phase M. tuberculosis cultures were diluted in 7H9 supplemented with 10% ADC 
and 0.2% glycerol to a final OD600 of 0.01. Aliquots of 100 μ L were then added to each well of a 96-well plate 
containing 100 μ L of 2-fold serial dilutions of each compound in duplicate. Sterility (no bacteria) and growth 
(no antibiotic) controls were also prepared. 30 μ L of resazurin (0.01%) were added to the growth control wells 
after 7 days of incubation at 37 °C, and the plates were incubated for additional 24 h. If a colour change from blue 
(oxidized state) to pink (reduced state), indicating bacterial growth, was observed, resazurin was added to the 
remaining wells and the plates were incubated at 37 °C for additional 24 h. The visual MIC was determined as the 
lowest antibiotic concentration which prevented colour change. The MIC of triclosan was also determined in 
combination with the efflux pump inhibitors CCCP (1.25 μ g/mL), reserpine (12 μ g/mL), verapamil (20 μ g/mL) 
and o-vanadate (9 μ g/mL).
Statistical analysis. Statistical analyses were performed using GraphPad Prism 5.02 (GraphPad Software, 
San Diego, USA). Normality of data was tested by use of the D’Agostino & Pearson omnibus normality test. 
According to this, differences were assessed by use of the non-parametric Mann-Whitney test, or the t test for 
normal data. The difference was considered to be statistically significant when p < 0.05.
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